US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

45.33

-0.0435-0.10%

Post-market: 46.020.6925+1.53%19:30 EDT

Volume:1K

Turnover:49.11K

Market Cap:124.97M

PE:- -

High:46.37

Open:45.39

Low:45.33

Close:45.37

52wk High:48.78

52wk Low:27.68

Shares:2.76M

Float Shares:2.76M

Volume Ratio:0.38

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Cogent Biosciences, Inc. : Leerink Partners Cuts Target Price to $60 from $72

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)

Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares

Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029

Xinjiang Bai Hua Clarifies No Role in Innovative Drug Development

Cogent Biosciences, Inc. : Guggenheim Raises Target Price to $52 from $45

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tvardi Therapeutics (TVRD)

AI Reshapes Drug Discovery Foundation, Domestic Industry Chain Expected to Benefit

Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares

Cogent Biosciences Files for USD 400 Million At-the-Market Stock Offering

Cogent Biosciences - May Offer up to $400 Mln in Common Stock Through Guggenheim Securities - SEC Filing

THOMSON REUTERS

Sana Biotechnology Q2 Adjusted Loss Narrows, Beats Estimates

Bionano Genomics Q2 Revenue Rises on Increased Clinical Adoption

Cell Therapy Developer ProKidney's Q2 Operating Loss Widens as Trial Costs Rise

Metagenomi Q2 Net Loss Widens Cash Runway Seen Through 2027

Harrow Q2 Revenue Slightly Beats Estimates

Guardant Health Grants 46,044 RSUs to 149 New Employees Under Inducement Plan

Rocket Pharmaceuticals Posts Q2 Profit Helped by PRV Sale

Olema Pharmaceuticals Q2 Net Loss Widens on Higher Clinical Trial Spending

Biohaven Q2 Net Loss Narrows on Lower R&D Spend

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/LFSC/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":45.3275,"timestamp":1789156800000,"preClose":45.371,"halted":0,"volume":1074,"hourTrading":{"tag":"盘后","latestPrice":46.02,"preClose":45.3275,"latestTime":"19:30 EDT","volume":10,"amount":452.9875,"timestamp":1789169406017,"change":0.6925,"changeRate":0.015278,"amplitude":0},"delay":0,"changeRate":-0.0009587622049327025,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"Market Closed","change":-0.0435,"latestTime":"09-11 16:00:00 EDT","open":45.39,"high":46.37,"low":45.3275,"amount":49106.001516000004,"amplitude":0.022977,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":45.371,"sharesOutstanding":2657035,"nav":45.4,"aum":125169389,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":46.02,"preClose":45.3275,"latestTime":"19:30 EDT","volume":10,"amount":452.9875,"timestamp":1789169406017,"change":0.6925,"changeRate":0.015278,"amplitude":0},"volumeRatio":0.3761557674902608},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3761557674902608,"shares":2757035,"dividePrice":0,"high":46.37,"amplitude":0.022977,"preClose":45.371,"low":45.3275,"week52Low":27.6794,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":45.3275,"eps":0,"divideRate":0,"volume":1074,"delay":0,"ttmEps":0,"open":45.39,"prevYearClose":36.6147,"prevWeekClose":46.1341,"prevMonthClose":45.79,"prevQuarterClose":45.2033,"fiveDayClose":46.1466,"twentyDayClose":46.8217,"sixtyDayClose":40.4233},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658970686","title":"Cogent Biosciences, Inc. : Leerink Partners Cuts Target Price to $60 from $72","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970686","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658970686?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:00","pubTimestamp":1786539637,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","COGT","CANC","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974286","title":"Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974286?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:40","pubTimestamp":1786534824,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Travere Therapeutics (TVTX), Maze Therapeutics, Inc....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-travere-therapeutics-tvtx-maze-therapeutics-inc-maze-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-travere-therapeutics-tvtx-maze-therapeutics-inc-maze-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FFTY","HCSG","BK4588","LU0128526141.USD","MAZE","LU0029874061.USD","BK4581","LABU","BK4007","BK4139","XBI","LFSC","XLV","TVTX","BK4563","BK4137","BK4585","IMNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658949165","title":"Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2658949165","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658949165?lang=en_us&edition=fundamental","pubTime":"2026-08-12 06:23","pubTimestamp":1786487005,"startTime":"0","endTime":"0","summary":"Guardant Health Chief Commercial Officer Chris Freeman disposes of $ 10.75 million in common sharesGuardant Health Chief Commercial Officer Chris Freeman exercised stock options for 63,605 shares on A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL4khYKk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4535","GDOC","LU0320765992.SGD","BK4585","GNOM","BK4196","FFOX","GH","GNMX","HELX","BK4551","BK4588","PTH","LFSC","EKG","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658657916","title":"Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2658657916","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658657916?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:01","pubTimestamp":1786456868,"startTime":"0","endTime":"0","summary":"Neurogene ( ($NGNE) ) just unveiled an announcement. Neurogene reported strong progress in its NGN-401 gene therapy program for Rett syndrome, high...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurogene-advances-rett-gene-therapy-program-and-extends-cash-runway-to-2029?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurogene-advances-rett-gene-therapy-program-and-extends-cash-runway-to-2029?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IBBQ","SYNB","BK4585","FBT","CNCR","GNOM","IBB","TBXU","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174341976","title":"Xinjiang Bai Hua Clarifies No Role in Innovative Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1174341976","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174341976?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:08","pubTimestamp":1786450094,"startTime":"0","endTime":"0","summary":"Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. (600721.SH) has issued a stock trading risk warning announcement, stating that it is a CRO enterprise primarily focused on the research and development of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GSKH","BIOY","XLVI","BK0216","BBP","600721","BK4585","SBIO","LFSC","IBB","PBE","WRND","APXH","GDOC","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997334","title":"Cogent Biosciences, Inc. : Guggenheim Raises Target Price to $52 from $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997334?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:35","pubTimestamp":1786448103,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN44813Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","CANC","LFSC","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658372967","title":"Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tvardi Therapeutics (TVRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658372967","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658372967?lang=en_us&edition=fundamental","pubTime":"2026-08-11 14:30","pubTimestamp":1786429817,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-spyre-therapeutics-syre-stereotaxis-stxs-and-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-spyre-therapeutics-syre-stereotaxis-stxs-and-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU0128526141.USD","BK4585","STXS","BK4137","BK4139","LABU","LU0029874061.USD","SYRE","XBI","XLV","TVRD","BK4082","LFSC","HCSG","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118729610","title":"AI Reshapes Drug Discovery Foundation, Domestic Industry Chain Expected to Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=1118729610","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118729610?lang=en_us&edition=fundamental","pubTime":"2026-08-11 14:12","pubTimestamp":1786428745,"startTime":"0","endTime":"0","summary":"A research report from Orient Securities Company Limited highlights that as global regulatory shifts accelerate, the large-scale application of AI in pharmaceuticals is rapidly advancing. It has...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIPO","QTOC","BK1147","ARTY","BK0028","WRND","BK0012","BK1564","XLVI","LFSC","BK0276","BK0188","BK4585","BK0183","APXH","600958","BIOY","CHAT","BBP","GDOC","SBIO","03958","IBB","GSKH","BK4588","VTHR","PBE","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658696533","title":"Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2658696533","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658696533?lang=en_us&edition=fundamental","pubTime":"2026-08-11 09:32","pubTimestamp":1786411952,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics director Jeffrey W. Albers disposes of USD 2.39 million in common sharesSpyre Therapeutics director Jeffrey W. Albers exercised stock options to buy 5,000 common shares at USD 10.39","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL7DPBBq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658339952","title":"Cogent Biosciences Files for USD 400 Million At-the-Market Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2658339952","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658339952?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:20","pubTimestamp":1786396815,"startTime":"0","endTime":"0","summary":"Cogent Biosciences files for USD 400 million at-the-market stock offeringCogent Biosciences set an at-the-market equity offering of up to USD 400 million under its sales agreement with Guggenheim Secu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL5kPmbQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","BK4139","CANC","LFSC","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952825","title":"Cogent Biosciences - May Offer up to $400 Mln in Common Stock Through Guggenheim Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952825?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:18","pubTimestamp":1786396717,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471SE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","COGT","BK4505","CANC","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951818","title":"Sana Biotechnology Q2 Adjusted Loss Narrows, Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951818","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951818?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:24","pubTimestamp":1786393458,"startTime":"0","endTime":"0","summary":"Sana Biotechnology Q2 adjusted loss narrows, beats estimatesOverviewCell therapy developer's Q2 adjusted loss per share beat analyst expectationsQ2 adjusted net loss also beat analyst expectationsComp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SANA","COGT","BK4139","CANC","LFSC","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951894","title":"Bionano Genomics Q2 Revenue Rises on Increased Clinical Adoption","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951894","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951894?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:24","pubTimestamp":1786393456,"startTime":"0","endTime":"0","summary":"Bionano Genomics Q2 revenue rises on increased clinical adoptionOverviewGenome analysis solutions provider's Q2 revenue rose 21% yr/yr to $8.2 mlnGross margin for Q2 improved to 53% from 52% a year ea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470WJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNGO","BK4505","QTRX","CANC","BK4121","LFSC","COGT","BK4575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658518889","title":"Cell Therapy Developer ProKidney's Q2 Operating Loss Widens as Trial Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2658518889","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658518889?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:22","pubTimestamp":1786393334,"startTime":"0","endTime":"0","summary":"Cell therapy developer ProKidney's Q2 operating loss widens as trial costs riseOverviewU.S. cell therapy developer's Q2 operating expenses rose, driven by clinical study and manufacturing costsNet los","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470W0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4139","BK4505","COGT","CANC","PROK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959032","title":"Metagenomi Q2 Net Loss Widens Cash Runway Seen Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959032","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959032?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:21","pubTimestamp":1786393289,"startTime":"0","endTime":"0","summary":"Metagenomi Q2 net loss widens cash runway seen through 2027OverviewGenome editing firm's Q2 net loss widened to $27.5 mln, loss per share was $0.73Company ended Q2 with $120.7 mln in cash, expects run","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BK4007","CANC","TBPH","MGX","LFSC","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658295927","title":"Harrow Q2 Revenue Slightly Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658295927","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658295927?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:19","pubTimestamp":1786393164,"startTime":"0","endTime":"0","summary":"Harrow Q2 revenue slightly beats estimatesOverviewOphthalmic drug maker's Q2 revenue rose 11% yr/yr, slightly beating analyst expectationsCompany posted net loss per share of $0.46, down from profit l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470WT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","HRTX","BK4505","LFSC","HROW","BK4557","COGT","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658599689","title":"Guardant Health Grants 46,044 RSUs to 149 New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2658599689","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658599689?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:13","pubTimestamp":1786392812,"startTime":"0","endTime":"0","summary":"Guardant Health grants 46,044 RSUs to 149 new employees under inducement planGuardant Health set inducement RSU grants covering 46,044 common shares for 149 new non-executive hires, with an Aug. 3, 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL208d3j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","LU0109394709.USD","BK4585","BK4588","BK4196","GNOM","LFSC","PTH","LU0320765992.SGD","GDOC","BK4535","FFOX","GH","GNMX","HELX","LU0889565916.HKD","EKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658895955","title":"Rocket Pharmaceuticals Posts Q2 Profit Helped by PRV Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2658895955","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658895955?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:10","pubTimestamp":1786392651,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals posts Q2 profit helped by PRV saleOverviewUS biotech firm reported Q2 net income after KRESLADI approval and PRV saleR&D and G&A expenses fell yr/yr due to lower headcount and c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470UW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","RCKT","TBPH","LFSC","CANC","BK4139","QTRX","BK4007","COGT","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959530","title":"Olema Pharmaceuticals Q2 Net Loss Widens on Higher Clinical Trial Spending","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959530","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959530?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:10","pubTimestamp":1786392606,"startTime":"0","endTime":"0","summary":"Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spendingOverviewUS biopharmaceutical firm's Q2 net loss widened yr/yr due to higher clinical development spendingCompany completed enr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470V3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","COGT","BK4007","BK4505","OLMA","BK4139","LFSC","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959562","title":"Biohaven Q2 Net Loss Narrows on Lower R&D Spend","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959562","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959562?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:09","pubTimestamp":1786392543,"startTime":"0","endTime":"0","summary":"Biohaven Q2 net loss narrows on lower R&D spendOverviewU.S. biopharma firm's Q2 net loss narrowed yr/yr on lower R&D and preclinical spendingQ2 operating expenses fell sharply after strategic repriori","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","COGT","CANC","BK4007","TBPH","BK4139","BHVN","BK4505","LU1093756325.SGD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}